A Regulatory Approval Drove Heron (HRTX) Stock Higher
Heron Therapeutics, Inc. (NASDAQ: HRTX) witnessed a notable surge in its stock during the preceding trading session, marking an 18.86% increase to settle at $2.6150. An important regulatory clearance caused this increase in Heron’s stock price. An important regulatory clearance caused this increase in Heron’s stock price. Heron (HRTX) has officially declared that the U.S. Food and Drug Administration (FDA) has given the green light to its additional New Drug Application (NDA). The approved NDA for ZYNRELEF extended-release solution aims to broaden the product’s use in orthopedic and soft tissue surgery, encompassing procedures on the foot and ankle, as well